FullHope Biomedical Co (ROCO:7773) ROCE %: -6.27% (As of Dec. 2025)


ROCO:7773 FullHope Biomedical Co Ltd ROCO:7773
14 GF Score
Price NT$27.65
! 1 Warning Sign
View Full Analysis

What is FullHope Biomedical Co ROCE %?

FullHope Biomedical Co ROCO:7773 14 ROCE % is -6.27% as of Dec. 2025. GuruFocus rates ROCO:7773 with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. FullHope Biomedical Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -6.27%.

FullHope Biomedical Co  (ROCO:7773) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

FullHope Biomedical Co ROCE % Related Terms

FullHope Biomedical Co ROCE % Historical Data

* Premium members only.

The historical data trend for FullHope Biomedical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FullHope Biomedical Co ROCE % Chart

FullHope Biomedical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
0.00 -48.51 -12.56 -9.44 -6.73

FullHope Biomedical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial -8.58 -8.20 -11.07 -7.19 -6.27
ROCO:7773
14GF Score
FullHope Biomedical Co Ltd ROCO:7773
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

FullHope Biomedical Co ROCE % Calculation

FullHope Biomedical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-38.606/( ( (610.908 - 18.194) + (571.447 - 17.229) )/ 2 )
=-38.606/( (592.714+554.218)/ 2 )
=-38.606/573.466
=-6.73 %

FullHope Biomedical Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-35.304/( ( (587.857 - 15.301) + (571.447 - 17.229) )/ 2 )
=-35.304/( ( 572.556 + 554.218 )/ 2 )
=-35.304/563.387
=-6.27 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -6.27% mean?
FullHope Biomedical Co (ROCO:7773) has a ROCE % of -6.27% as of Dec. 2025.
Is FullHope Biomedical Co's ROCE % too high?
FullHope Biomedical Co's current ROCE % is -6.27%. Overall, FullHope Biomedical Co has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does FullHope Biomedical Co's ROCE % compare to VRTX and REGN?
FullHope Biomedical Co's ROCE % of -6.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. FullHope Biomedical Co's current ROCE % is -6.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FullHope Biomedical Co stock overvalued right now?
FullHope Biomedical Co (ROCO:7773) has a current ROCE % of -6.27%. The current ROCE % is -6.27%. FullHope Biomedical Co's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For FullHope Biomedical Co (ROCO:7773), the current ROCE % is -6.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FullHope Biomedical Co Business Description

Address Lane 609, Sector. 5, Chongxin Road, 10th Floor, No. 10, Sanchong District, New Taipei City, TWN
FullHope Biomedical Co Ltd focuses on immune system-related services and innovative R&D. It establishes cell-based immunotherapies for cancers and autoimmune disorders. Its services are, Immunoprofiling, Circulating Tumor Cells Testing, Regulation of Cell Therapy, Contracting Immune Cell Manufacturing, Immune Cell Bank, Contract Research Organization, and Endotoxin and Mycoplasma Detection Service.
14GF Score

Get the complete analysis for ROCO:7773

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.65
Price